Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26187793 | 0.94 | KMT2A (0.44) | KMT2AMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL21531127 | 0.85 | KMT2A (0.60) | KMT2AMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23705289 | 0.84 | MAPT (0.46) | KMT2AMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL26187791 | 0.84 | ALDH1A1 (0.38) | KMT2AMAPTKDM4EALDH1A1POLB | |
| SCHEMBL26187897 | 0.82 | LGALS3 (0.36) | KMT2AMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23705002 | 0.82 | MAPT (0.49) | KMT2AMAPTKDM4EALDH1A1POLB | |
| SCHEMBL29184484 | 0.81 | MAPT (0.48) | KMT2AMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30103381 | 0.81 | MAPT (0.47) | KMT2AMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28845233 | 0.79 | MAPT (0.49) | KMT2AMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL26187915 | 0.79 | KMT2A (0.41) | KMT2AMAPTSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250388614-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4658263-A2 | COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS | Yale University (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250161460-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2025-05-22 | — | — | US | disclosed |
| US-12234256-B2 | Molecular degraders of extracellular proteins | YALE UNIVERSITY (US) | 2025-02-25 | — | — | US | disclosed |
| US-12128105-B2 | Molecular degraders of extracellular proteins | YALE UNIVERSITY (US) | 2024-10-29 | — | — | US | disclosed |
| WO-2024163610-A2 | COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS | YALE UNIVERSITY (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4392430-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | Yale University (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4392075-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | Yale University (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2023028590-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023028597-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | KMT2A 4686/4885MAPT 4545/4885SMN1; SMN2 3100/4885 |
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, COL2A1, FCGR2A | KMT2A 3413/4885MAPT 4585/4885SMN1; SMN2 4099/4885 |
| US-20250161460-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | KMT2A 4686/4885MAPT 4545/4885SMN1; SMN2 3100/4885 |
| US-12128105-B2 | Molecular degraders of extracellular proteins | ASGR1, MSR1, LDLR | KMT2A 4686/4885MAPT 4545/4885SMN1; SMN2 3100/4885 |
| US-20250388614-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, COL2A1, LDLR | KMT2A 4024/4885MAPT 4539/4885SMN1; SMN2 3414/4885 |
| US-12234256-B2 | Molecular degraders of extracellular proteins | ASGR1, MSR1, LDLR | KMT2A 4686/4885MAPT 4545/4885SMN1; SMN2 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.